Direct-infusion based metabolomics unveils biochemical profiles of inborn errors of metabolism in cerebrospinal fluid

Hanneke A Haijes; Maria van der Ham; Johan Gerrits; Peter M van Hasselt; Hubertus C M T Prinsen; Monique G M de Sain-van der Velden; Nanda M Verhoeven-Duif; Judith J M Jans

doi:10.1016/j.ymgme.2019.03.005

Direct-infusion based metabolomics unveils biochemical profiles of inborn errors of metabolism in cerebrospinal fluid

Mol Genet Metab. 2019 May;127(1):51-57. doi: 10.1016/j.ymgme.2019.03.005. Epub 2019 Mar 15.

Authors

Hanneke A Haijes¹, Maria van der Ham², Johan Gerrits², Peter M van Hasselt³, Hubertus C M T Prinsen², Monique G M de Sain-van der Velden², Nanda M Verhoeven-Duif², Judith J M Jans⁴

Affiliations

¹ Section Metabolic Diagnostics, Department of Biomedical Genetics, Centre for Molecular Medicine, University Medical Centre Utrecht, Utrecht University, Lundlaan 6, 3584 EA Utrecht, The Netherlands; Section Metabolic Diseases, Department of Child Health, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht University, Lundlaan 6, 3584 EA Utrecht, The Netherlands.
² Section Metabolic Diagnostics, Department of Biomedical Genetics, Centre for Molecular Medicine, University Medical Centre Utrecht, Utrecht University, Lundlaan 6, 3584 EA Utrecht, The Netherlands.
³ Section Metabolic Diseases, Department of Child Health, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht University, Lundlaan 6, 3584 EA Utrecht, The Netherlands.
⁴ Section Metabolic Diagnostics, Department of Biomedical Genetics, Centre for Molecular Medicine, University Medical Centre Utrecht, Utrecht University, Lundlaan 6, 3584 EA Utrecht, The Netherlands. Electronic address: J.J.M.Jans@umcutrecht.nl.

PMID: 30926434
DOI: 10.1016/j.ymgme.2019.03.005

Abstract

Background: For inborn errors of metabolism (IEM), metabolomics is performed for three main purposes: 1) development of next generation metabolic screening platforms, 2) identification of new biomarkers in predefined patient cohorts and 3) for identification of new IEM. To date, plasma, urine and dried blood spots are used. We anticipate that cerebrospinal fluid (CSF) holds additional - valuable - information, especially for IEM with neurological involvement. To expand metabolomics to CSF, we here tested whether direct-infusion high-resolution mass spectrometry (DI-HRMS) based non-quantitative metabolomics could correctly capture the biochemical profile of patients with an IEM in CSF.

Methods: Eleven patient samples, harboring eight different IEM, and thirty control samples were analyzed using DI-HRMS. First we assessed whether the biochemical profile of the control samples represented the expected profile in CSF. Next, each patient sample was assigned a 'most probable diagnosis' by an investigator blinded for the known diagnoses of the patients.

Results: the biochemical profile identified using DI-HRMS in CSF samples resembled the known profile, with - among others - the highest median intensities for mass peaks annotated with glucose, lactic acid, citric acid and glutamine. Subsequent analysis of patient CSF profiles resulted in correct 'most probable diagnoses' for all eleven patients, including non-ketotic hyperglycinaemia, propionic aciduria, purine nucleoside phosphorylase deficiency, argininosuccinic aciduria, tyrosinaemia type I, hyperphenylalaninemia and hypermethioninaemia.

Conclusion: We here demonstrate that DI-HRMS based non-quantitative metabolomics accurately captures the biochemical profile of this set of patients in CSF, opening new ways for using metabolomics in CSF in the metabolic diagnostic laboratory.

Keywords: CSF; Cerebrospinal fluid; DIMS; Direct-infusion mass spectrometry; IEM; Inborn errors of metabolism; Metabolomics.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers / cerebrospinal fluid
Humans
Mass Spectrometry
Metabolism, Inborn Errors / cerebrospinal fluid*
Metabolism, Inborn Errors / diagnosis*
Metabolomics / methods*

Substances

Biomarkers